

University of Groningen

## Molecular imaging to guide clinical decisions on targeted treatment of solid tumors

Oosting-Lenstra, Sjoukje Femmy

**IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you wish to cite from it. Please check the document version below.**

*Document Version*

Publisher's PDF, also known as Version of record

*Publication date:*

2014

[Link to publication in University of Groningen/UMCG research database](#)

*Citation for published version (APA):*

Oosting-Lenstra, S. F. (2014). *Molecular imaging to guide clinical decisions on targeted treatment of solid tumors*. [Thesis fully internal (DIV), University of Groningen]. s.n.

### Copyright

Other than for strictly personal use, it is not permitted to download or to forward/distribute the text or part of it without the consent of the author(s) and/or copyright holder(s), unless the work is under an open content license (like Creative Commons).

The publication may also be distributed here under the terms of Article 25fa of the Dutch Copyright Act, indicated by the "Taverne" license. More information can be found on the University of Groningen website: <https://www.rug.nl/library/open-access/self-archiving-pure/taverne-amendment>.

### Take-down policy

If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim.

Downloaded from the University of Groningen/UMCG research database (Pure): <http://www.rug.nl/research/portal>. For technical reasons the number of authors shown on this cover page is limited to 10 maximum.

# **Chapter 12**

## **Publications**

1. Oosting-Lenstra SF, Van Marwijk Kooy M. Failure of CHOP with rituximab for lymphomatoid granulomatosis. *Neth J Med* 2007;65:442-7.
2. Oldenhuis CNAM, Oosting SF, Gietema JA, De Vries EGE. Prognostic versus predictive value of biomarkers in oncology. *Eur J Cancer*. 2008;44:946-53.
3. Oosting SF, De Haas EC, Links TP, De Bruin D, Sluiter WJ, De Jong IJ, Hoekstra HJ, Sleijfer DT, Gietema JA. Prevalence of paraneoplastic hyperthyroidism in patients with metastatic non-seminomatous germ cell tumors. *Ann Oncol* 2010;21:104-8.
4. Oosting S, Nagengast W, De Vries E. More on bevacizumab in hereditary hemorrhagic telangiectasia. *N Engl J Med* 2009;361:931.
5. De Haas EC, Oosting SF, Lefrandt JD, Wolffenbuttel BH, Sleijfer DT, Gietema JA. The metabolic syndrome in cancer survivors. *Lancet Oncol* 2010;11:193-203.
6. Oosting SF, Peters FTM, Hospers GAP, Mulder NH. A patient with metastatic melanoma presenting with gastrointestinal perforation after dacarbazine: a case report. *J Med Case Reports* 2010;4:10.
7. Nagengast WB, Lub-de Hooge MN, Oosting SF, Den Dunnen WF, Warnders FJ, Brouwers AH, de Jong JR, Price PM, Hollema H, Hospers GA, Elsinga Ph, Hesselink JW, Gietema JA, De Vries EG. VEGF-PET imaging is a non-invasive biomarker showing differential changes in the tumor during sunitinib treatment. *Cancer Res* 2011;71:143-35.
8. Langendijk JA, Oosting SF. Grading system and management guidelines for dermatitis induced by head and neck radiotherapy plus cetuximab: clinical validation required. *Ann Oncol* 2011; 22: 2157-9.
9. Van Spaendonck-Zwarts KY, Badeloe S, Oosting SF, Hovenga S, Semmelink HJ, Van Moorselaar RJ, Van Waesberghe JH, Mensenkamp AR, Menko FH. Hereditary leiomyomatosis and renal cell cancer presenting as metastatic kidney cancer at 18 years of age: implications for surveillance. *Fam Cancer* 2012;11:123-9.
10. Vermaat JS, Gerritse FL, Van der Veldt AA, Roessingh WM, Niers TM, Oosting SF, Sleijfer S, Roodhart JM, Beijnen JH, Schellens JH, Gietema JA, Boven E, Richel DJ, Haanen JB, Voest EE. Validation of serum amyloid  $\alpha$  as an independent biomarker for progression-free and overall survival in metastatic renal cell cancer patients. *Eur Urol* 2012;62:685-95.
11. Eechoute K, Van der Veldt AAM, Oosting S, Kappers MHW, Wessels JAM, Gelderblom H, Guchelaar H-J, Reyners AKL, Van Herpen CML, Haanen JB, Mathijssen RHJ, Boven E. Polymorphisms in endothelial nitric oxide synthetase (eNOS) and vascular endothelial growth factor (VEGF) predict sunitinib-induced hypertension. *Clin Pharmacol Ther* 2012;94:503-10.
12. Boomsma MJ, Bijl HP, Christianen ME, Beetz I, Chouvalova O, Steenbakkers RJ, van der Laan BF, Wolffenbuttel BH, Oosting SF, Schilstra C, Langendijk JA. Prospective

- cohort study on radiation-induced hypothyroidism: development of an NTCP model. *Int J Radiat Oncol Biol Phys* 2012;84:e351-6.
13. Arjaans M, Oude Munnink TH, Oosting SF, Terwisscha van Scheltinga AG, Gietema JA, Garbacik ET, Timer-Bosscha H, Lub-de Hooge MN, Schröder CP, De Vries EG. Bevacizumab-induced normalization of blood vessels in tumors hampers antibody uptake. *Cancer Res* 2013;73:3347-55.
  14. Arjaans M, Oosting SF, Schroder CP, De Vries EG. Bevacizumab-induced normalization of blood vessels in tumors hampers antibody uptake-response. *Cancer Res* 2013;73:7147-7148.